PNC Financial Services Group Inc. Sells 11,118 Shares of DexCom, Inc. $DXCM

PNC Financial Services Group Inc. trimmed its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 19.3% during the third quarter, Holdings Channel.com reports. The firm owned 46,437 shares of the medical device company’s stock after selling 11,118 shares during the period. PNC Financial Services Group Inc.’s holdings in DexCom were worth $3,125,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of DXCM. Andra AP fonden bought a new stake in DexCom during the 2nd quarter valued at $26,000. Twin Peaks Wealth Advisors LLC bought a new stake in shares of DexCom during the second quarter worth about $26,000. SJS Investment Consulting Inc. raised its holdings in shares of DexCom by 4,800.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after acquiring an additional 384 shares during the last quarter. Financial Consulate Inc. bought a new position in DexCom in the 3rd quarter valued at about $29,000. Finally, Sound Income Strategies LLC boosted its stake in DexCom by 83.8% during the 3rd quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 285 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Wells Fargo & Company lowered their price objective on DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. Argus lowered their price target on DexCom from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, November 7th. BTIG Research reaffirmed a “buy” rating and set a $85.00 price objective on shares of DexCom in a report on Friday, February 13th. JPMorgan Chase & Co. lowered their target price on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating for the company in a report on Friday, October 31st. Finally, Barclays reissued an “underweight” rating and set a $72.00 price target (up from $71.00) on shares of DexCom in a research report on Friday, February 13th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $85.18.

DexCom Trading Up 1.1%

NASDAQ DXCM opened at $73.08 on Friday. The business’s fifty day moving average is $69.49 and its 200-day moving average is $69.31. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59. The stock has a market capitalization of $28.13 billion, a price-to-earnings ratio of 34.80, a PEG ratio of 1.42 and a beta of 1.49. DexCom, Inc. has a one year low of $54.11 and a one year high of $91.87.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03. The company had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The firm’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.45 earnings per share. Equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.